High-affinity rabbit monoclonal antibody of anti-doproliumab and application of high-affinity rabbit monoclonal antibody

By developing high-affinity rabbit monoclonal antibodies and competitive enzyme-linked immunoassay detection methods, the sensitivity problem of the blood concentration detection of the current technology of moderate primulinumab is solved, high sensitivity and specific detection are achieved, and drug efficacy is ensured and safety monitoring.

CN118909130AActive Publication Date: 2024-11-08PUJIAN BIOLOGICAL (WUHAN) TECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411166274.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-08
Estimated Expiration
2044-08-23

AI Technical Summary

Technical Problem

Existing detection technologies are difficult to detect blood drug concentrations of Dupilumab with high sensitivity, which affects the monitoring of drug efficacy data and safety data.

Method used

A high-affinity rabbit monoclonal antibody was developed, using monoclonal antibody development technology for screening and culture of single B lymphocytes, to prepare a competitive ELISA detection kit that can detect priliumab with high sensitivity, and combines Biacore instruments to determine affinity. , and established high sensitivity and high specificity competition method enzyme-linked immunoassay detection methods.

Benefits of technology

Achieve high sensitivity detection of Duprilumab, which can accurately monitor the total drug concentration and free drug concentration of drugs in clinical diagnosis and scientific research, and does not cross-react with human IgG4 and human total IgG, showing strong specificity Sex and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909130A_ABST
    Figure CN118909130A_ABST
Patent Text Reader

Abstract

The invention discloses a high-affinity rabbit monoclonal antibody for resisting duprole uliumab and application of the high-affinity rabbit monoclonal antibody, and relates to the technical field of monoclonal antibody preparation. The high-affinity rabbit monoclonal antibody provided by the invention is a first antibody or a second antibody; the amino acid sequence of a heavy chain of the first antibody is as shown in SEQ ID NO.8, and the amino acid sequence of a light chain of the first antibody is as shown in SEQ ID NO.9; the amino acid sequence of the heavy chain of the second antibody is shown as SEQ ID NO.17, and the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.18. The invention also provides biological materials such as nucleic acid molecules for coding the rabbit monoclonal antibody, recombinant strains and the like, and a drug and a product for detecting the duopril antibody. The rabbit monoclonal antibody provided by the invention has high affinity, detection sensitivity and specificity to dupiliumab, and can be used for diagnosing the total drug concentration and free drug concentration of dupiliumab in the body of an injection patient; and no cross reaction with human IgG4 and human total IgG exists.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of monoclonal antibody preparation, and in particular to a high-affinity rabbit monoclonal antibody resistant to dupilumab and applications thereof. Background Art

[0002] Interleukin-4 receptor (IL-4R, also known as CD124; IL4Rα) is a type I transmembrane protein and a member of the interleukin family. Human IL4Rα is 825 amino acids long and contains a signal peptide, an extracellular region, a transmembrane region, and an intracellular region. IL4Rα can regulate the production of IgE and the production of chemokines and mucus by binding to IL-4 and IL-13. IL4Rα plays a key role in the occurrence of allergic reactions and asthma.

[0003] Dupilumab ( Dupilumab ) is a fully human IL-4Rα monoclonal antibody jointly developed by Sanofi and Regeneron. It can specifically bind to the IL-4Rα subunit, competitively bind to IL-4 and IL-13 / IL-13Rα1 complex, block IL-4 and IL-13-induced IL-4Rα-mediated signal transduction, block the type 2 inflammatory pathway, reduce the pathological response of type 2 inflammation, and thus inhibit type 2 inflammatory response.

[0005] Based on the above research results, dupilumab ( Dupilumab ) is a fully humanized drug for the treatment of moderate to severe atopic dermatitis, moderate to severe asthma and chronic rhinitis in children and adults. In the clinical treatment process, the blood concentration monitoring of antibody drugs is very important for the efficacy and safety data of the drug. Therefore, it is necessary to develop a method that can detect dupilumab ( Dupilumab )’s blood drug concentration detection technology is of great significance. Summary of the invention

[0006] The present invention provides a high-affinity rabbit monoclonal antibody against Dupilumab and its application. The monoclonal antibody is prepared by using Dupilumab as an immunogen and a monoclonal antibody development technology based on single B lymphocyte screening and culture. The monoclonal antibody has high affinity to Dupilumab. Dupilumab ) has high detection sensitivity. This is achieved through the following technologies.

[0007] A high-affinity rabbit monoclonal antibody against dupilumab, wherein the high-affinity rabbit monoclonal antibody is a first antibody or a second antibody; The amino acid sequence of the complementary determining region CDR1 on the heavy chain of the first antibody is shown in SEQ ID NO.1; The amino acid sequence of the complementary determining region CDR2 on the heavy chain of the first antibody is shown in SEQ ID NO.2; The amino acid sequence of the complementary determining region CDR3 on the heavy chain of the first antibody is shown in SEQ ID NO.3; The amino acid sequence of the complementary determining region CDR1 on the light chain of the first antibody is shown in SEQ ID NO.4; The amino acid sequence of the complementary determining region CDR2 on the light chain of the first antibody is GAS; The amino acid sequence of the complementary determining region CDR3 on the light chain of the first antibody is shown in SEQ ID NO.5; The amino acid sequence of the complementary determining region CDR1 on the heavy chain of the second antibody is shown in SEQ ID NO.10; The amino acid sequence of the complementary determining region CDR2 on the heavy chain of the second antibody is shown in SEQ ID NO.11; The amino acid sequence of the complementary determining region CDR3 on the heavy chain of the second antibody is shown in SEQ ID NO.12; The amino acid sequence of the complementary determining region CDR1 on the light chain of the second antibody is shown in SEQ ID NO.13; The amino acid sequence of the complementary determining region CDR2 on the light chain of the second antibody is AAS; The amino acid sequence of the complementary determining region CDR3 on the light chain of the second antibody is shown in SEQ ID NO.14.

[0008] The present invention is used to prepare the above-mentioned anti-duplimab ( Dupilumab ) The immunogen of the rabbit monoclonal antibody is a fully human monoclonal antibody (IgG4 type) that targets interleukin-4 receptor subunit α (IL-4R-α) and is prepared by expression; the preparation method is a monoclonal antibody development technology based on single B lymphocyte screening and culture.

[0009] Furthermore, the amino acid sequence of the heavy chain variable region of the first antibody is shown as SEQ ID NO.6; the amino acid sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.7.

[0010] Furthermore, the amino acid sequence of the heavy chain of the first antibody is shown as SEQ ID NO.8; the amino acid sequence of the light chain of the first antibody is shown as SEQ ID NO.9.

[0011] Furthermore, the amino acid sequence of the heavy chain variable region of the second antibody is shown in SEQ ID NO.15; the amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.16.

[0012] Furthermore, the amino acid sequence of the heavy chain of the second antibody is shown as SEQ ID NO.17; and the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.18.

[0013] The present invention also provides a substance, which comprises any one of the following aspects: (1) A nucleic acid molecule or a vector comprising the nucleic acid molecule, wherein the nucleic acid encodes the high-affinity rabbit monoclonal antibody; (2) A modified cell or recombinant strain, wherein the modified cell or recombinant strain is used to express the above-mentioned high-affinity rabbit monoclonal antibody; (3) An antibody derivative, comprising the above-mentioned high-affinity rabbit monoclonal antibody; (4) A drug, wherein the drug composition comprises a therapeutically effective amount of the above-mentioned high-affinity rabbit monoclonal antibody, or the antibody derivative; (5) A detection product, comprising the above-mentioned high-affinity rabbit monoclonal antibody, or the above-mentioned nucleic acid molecule, or the above-mentioned vector, or a derivative of the above-mentioned high-affinity rabbit monoclonal antibody.

[0014] Furthermore, the detection product is a competitive ELISA detection kit for detecting dupilumab.

[0015] Furthermore, in the competitive ELISA detection kit for detecting dupilumab, the first antibody is a competitive antibody and the second antibody is a non-competitive antibody.

[0016] The present invention also provides the application of the above-mentioned high-affinity rabbit monoclonal antibody against Dupilumab, which is used for detecting Dupilumab for purposes other than disease diagnosis and treatment; or, for preparing a product for detecting Dupilumab; or, for preparing a product for regulating the activity of Dupilumab.

[0017] Furthermore, the product is a detection reagent, a detection kit, a detection test strip, a detection probe or a detection chip.

[0018] The present invention provides a method for detecting dupilumab ( Dupilumab ) products and methods, all of which use the anti-duplimab (first antibody and / or second antibody) provided by the present invention. The "not for the purpose of disease diagnosis and treatment" claimed in the present invention means that except for clinical use for diagnosis or detection of dupilumab ( Dupilumab) other applications and methods other than therapeutic effects, such as scientific research in the laboratory. Of course, the high-affinity rabbit monoclonal antibody provided by the present invention can detect dupilumab ( Dupilumab ) can actually be used clinically for qualitative and quantitative detection of dupilumab ( Dupilumab ) scene.

[0019] Compared with the prior art, the present invention is beneficial in that: 1. The anti-duplimab provided by the present invention ( Dupilumab ) high affinity rabbit monoclonal antibody, the affinity of the primary antibody and the secondary antibody was determined using a Biacore instrument, the primary antibody and Dupilumab ( Dupilumab ) The affinity constant of the binding is 7.36×10 -11 M, secondary antibody and dupilumab ( Dupilumab ) The affinity constant of the binding is 9.45×10 -11 M; Dupilumab ( Dupilumab ) or preparation of a test kit for dupilumab ( Dupilumab ) products.

[0020] 2. The present invention also develops a highly sensitive and highly specific dupilumab ( Dupilumab ) competitive enzyme-linked immunosorbent assay method has important significance in clinical diagnosis and scientific research applications. The dupilumab ( Dupilumab ) Competitive enzyme-linked immunosorbent assay method, the competitive antibody is the first antibody in the present invention, and the non-competitive antibody is the second antibody. When the standard sample is Dupilumab ( Dupilumab ), the IC50 of the first antibody was 64.59 ng / mL, and the second antibody showed no competition. The established method can be used to diagnose dupilumab ( Dupilumab ) Total drug concentration and free drug concentration in the injected patients; no cross reaction with human IgG4 and total human IgG. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a graph showing the serum titer after animal immunization in Example 1.

[0022] Figure 2 This is the sorting result of B lymphocytes in Example 1.

[0023] Figure 3 This is the gel electrophoresis diagram of two recombinant rabbit monoclonal antibodies in Example 1.

[0024] Figure 4 The results of affinity testing of the first antibody at different concentrations in Example 2 are shown.

[0025] Figure 5 The results of affinity testing of the second antibody at different concentrations in Example 2 are shown.

[0026] Figure 6 This is the standard curve (inhibition rate curve) of the competitive enzyme-linked immunosorbent assay method established using the first antibody and the second antibody in Example 3.

[0027] Figure 7 This is the specific detection result of the indirect enzyme-linked immunosorbent assay method established using the first antibody and the second antibody in Example 4.

[0028] Figure 8 This is the stability test result of the first antibody in Example 4.

[0029] Fig. 9 The stability test results of the second antibody in Example 4 are shown. DETAILED DESCRIPTION

[0030] The technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] In the implementation cases of the present invention, the term "nucleic acid (molecule)" may include a coding nucleic acid or a nucleic acid that also includes additional coding and / or non-coding sequences. The DNA form of the nucleic acid of the present invention includes but is not limited to cDNA, genomic DNA or artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. The nucleic acid encoding the high-affinity rabbit monoclonal antibody or its antigen-binding fragment described in the present invention includes but is not limited to a coding sequence that only encodes the structure of a mature high-affinity rabbit monoclonal antibody or its antigen-binding fragment; a coding sequence encoding a mature high-affinity rabbit monoclonal antibody or its antigen-binding fragment and various additional coding sequences; a coding sequence encoding a mature high-affinity rabbit monoclonal antibody or its antigen-binding fragment structure (and optional additional coding sequences) and non-coding sequences, etc.

[0032] In some embodiments of the present invention, the full-length nucleic acid sequence of the high-affinity rabbit monoclonal antibody or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. Once the relevant sequence is obtained, the relevant sequence can be obtained in large quantities by recombination. Generally, it is cloned into a vector, then transferred into cells, and then the relevant sequence is isolated from the host cells after proliferation by conventional methods. The biological molecules involved in the present invention (nucleic acids, high-affinity rabbit monoclonal antibodies and antigen-binding fragments thereof, etc.) include biological molecules in isolated form.

[0033] The vectors include viral vectors (such as adenoviral vectors, retroviral vectors, adeno-associated viral vectors) and non-viral vectors (plasmids, transposon vectors).

[0034] In some preferred embodiments, the vector is an expression vector.

[0035] The terms "vector", "cloning vector", "recombinant vector" or "expression vector" refer to a vector that can introduce DNA or RNA sequences into a host cell in a manner that transforms the host and promotes the expression (eg, transcription and translation) of the introduced sequence.

[0036] Other examples of plasmids include replicating plasmids comprising an origin of replication, or integrating plasmids.

[0037] The vector may be a recombinant expression vector or a cloning vector. The vector provided by the present invention (e.g., an expression vector) contains the nucleic acid sequence provided by the present invention encoding an antibody, at least one promoter operably connected to the nucleic acid sequence and / or at least one selection marker.

[0038] Examples of vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papovaviruses, lambda phage, M13 phage, plasmids, and the like.

[0039] The "transformed cell" provided by the present invention refers to the introduction of "foreign" (i.e., external or extracellular) genes or DNA or RNA sequences into host cells so that the host cells express the introduced genes or sequences to produce substances of interest, usually proteins encoded by the genes or introduced sequences. The host cells that receive and express the introduced DNA or RNA have been "transformed."

[0040] In a specific embodiment of the present invention, the host cell includes but is not limited to mammalian cells, insect cells, plant cells, fungal cells, prokaryotic cells and the like.

[0041] The present invention provides an antibody derivative, which comprises the high-affinity rabbit monoclonal antibody provided by the present invention, directly or indirectly connected to a complex formed by a connectable substance.

[0042] The attachable species include a detectable label, a drug, a toxin, a cytokine, a radionuclide or an enzyme.

[0043] In a specific embodiment of the present invention, the connectable substance is selected from: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing detectable products, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorods, viral particles, liposomes, nanomagnetic particles, prodrug activating enzymes (such as DT-diaphorase (DTD) or biphenyl hydrolase-like proteins (BPHL), chemotherapeutic agents (such as cisplatin)) or any form of nanoparticles, etc.

[0044] The term "detectable marker" refers to any part that generates a measurable signal by a change in the optical, electrical or other physical index of the molecular state coupled to the part. Such physical indexes include spectral, photochemical, biochemical, immunochemical, electromagnetic, radiochemical and chemical means, such as but not limited to fluorescence, chemiluminescence and chemiluminescence. When used with respect to a labeled detection agent, a "direct label" is a detectable label attached to the detection agent by any means. When used with respect to a labeled detection agent, an "indirect label" is a detectable label that specifically binds to the detection agent. Therefore, an indirect label includes the following parts: the specific binding partner of the detection agent. Biotin and avidin are examples of such parts that are used, for example, by contacting a biotinylated antibody with a labeled avidin to produce an indirectly labeled antibody.

[0045] The medicine provided by the present invention includes a pharmaceutically acceptable carrier or excipient. In some embodiments, the excipient includes a pharmaceutically acceptable solvent, a dispersant, an additive, a plasticizer, etc. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable carrier medium. The formulated pharmaceutical composition can be administered by conventional routes, including but not limited to: intratumoral, intraperitoneal, intravenous, or topical administration.

[0046] In other embodiments, the pharmaceutical composition is an aqueous pharmaceutical composition (e.g., an aqueous solution), or the high affinity rabbit monoclonal antibody is provided with a salt in water without a buffer, or comprises an aqueous buffer or other type of solvent (e.g., an organic solvent).

[0047] The term "effective amount" as used herein refers to an amount sufficient to achieve a beneficial or desired result. A "therapeutically effective amount" is an amount that achieves a desired therapeutic effect. This amount may be the same or different from a preventive effective amount, which is the amount required to prevent the onset of a disease or disease symptoms. An effective amount may be administered, applied or dosed once or more. The "therapeutically effective amount" (i.e., effective dose) of a therapeutic compound is determined according to the selected therapeutic compound. For example, the composition may be administered once or more per day, once or more per week, once or more per month, or once or more per year. Certain factors may affect the dosage and schedule required for the effective treatment of a subject, including but not limited to the severity of the disease or illness, previous treatment, the general health and / or age of the subject, and other diseases present.

[0048] Example 1: Anti-duplimab ( Dupilumab ) Preparation of rabbit monoclonal antibodies 1. Animal immunization

[0049] In order to obtain rabbit monoclonal antibodies that recognize dupilumab, the present invention uses dupilumab as an immunogen to immunize four New Zealand white rabbits (provided by Hubei Provincial Experimental Animal Research Center), which are marked as 1#, 2#, 3# and 4# respectively; each white rabbit is immunized with 250 μg; For the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant to form an emulsion, which was injected subcutaneously at multiple points in the abdomen and back. Two weeks later, 125 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant to form an emulsion, which was injected subcutaneously at multiple points in the abdomen and back for two booster immunizations. After three immunizations, the serum titer was determined by ELISA. Rabbits with high serum titer were selected and given a booster immunization with 125 μg of immunogen injected subcutaneously at multiple points. The spleen was taken out three days later.

[0050] like Figure 1 As shown, in each dilution multiple, the sera from 2# New Zealand white rabbit had the highest titer, so 2# New Zealand white rabbit was selected as the experimental subject to isolate the spleen.

[0051] 2. Spleen Cell Isolation The spleen of 2# New Zealand white rabbit was placed in DMEM basal culture medium containing 100 U / mL penicillin and 100 μg / mL streptomycin, cut into pieces with a surgical blade, and then transferred to a 100 μm cell mesh for grinding.

[0052] The obtained cell suspension was filtered to remove large cell aggregates and tissue capsules, centrifuged at 450 g for 7 min, and the spleen cell aggregates were retained after removing the supernatant.

[0053] The spleen cell pellet was resuspended in regular PBS buffer and the red blood cells were lysed, and then centrifuged again at 450 g for 7 min to retain the spleen cells.

[0054] The spleen cells were resuspended in DMEM basal medium containing 100 U / mL penicillin and 100 μg / mL streptomycin, centrifuged at 450 g for 7 min, and the resulting spleen cells were resuspended in complete medium (DMEM basal medium containing 15% fetal bovine serum, 100 U / mL penicillin and 100 μg / mL streptomycin) for later use.

[0055] 3. B lymphocyte sorting The specific method for sorting B lymphocytes can refer to the method disclosed in the Chinese patent CN110016462B "Method for efficiently separating single antigen-specific B lymphocytes from spleen cells". Figure 2 As shown in the figure, the R5 area is the sorted B lymphocytes, which are cultured in a 96-well cell culture plate, with one B lymphocyte cultured in each well.

[0056] 4. Cloning of the gene encoding rabbit monoclonal antibody The supernatant of cultured B cells was used to identify positive clones by antigen-coated ELISA, the positive control was prepared by diluting the immunized rabbit serum at 1:2000, and the negative control was PBS buffer, as shown in Table 1 below.

[0057] Table 1 Elisa results of B cell supernatant after culture (OD 450 and OD 620 The difference of

[0058] In Table 1, the serial numbers in the first row and the first column refer to the serial numbers of the 96-well ELISA plate; the data in bold and underlined fonts are the positive clones selected for the next step of the experiment. The cells of the positive clones were collected and lysed, and RNA was extracted and reverse transcribed into cDNA. Using cDNA as a template, under the action of DNA polymerase, the naturally paired rabbit monoclonal antibody light and heavy chain variable region genes (VH and VL) were amplified and sequenced through denaturation, annealing, and extension.

[0059] 5. Production and purification of monoclonal antibodies The rabbit monoclonal antibodies corresponding to the bold and underlined data in Table 1 above (i.e., B-5, C-9, D-3, D-7, F-1, and F-7) were used as the objects. In order to obtain multiple rabbit monoclonal antibodies that recognize dupilumab, the heavy chain and light chain genes of the rabbit monoclonal antibodies were loaded on expression vectors, respectively, and the plasmids were transfected into 293F cells; 72-96 hours after transfection, the culture supernatant containing recombinant rabbit monoclonal antibodies that recognize dupilumab was obtained.

[0060] The recombinant rabbit monoclonal antibody that recognizes Duplizumab was purified from the culture supernatant after transfection using protein G affinity gel resin. After antibody identification, the antibody was packaged and stored at -20°C for future use. The 6 strains in Table 1 were sequenced, and 4 strains failed to be sequenced and discarded (cell death during culture, or loss of antibody secretion ability, etc.). The gel electrophoresis of the remaining 2 recombinant rabbit monoclonal antibodies is shown in the figure below. Figure 3 As shown. Figure 3 As can be seen in the figure, the rabbit monoclonal antibody recombinant antibody bands are uniform, the molecular weight is correct, and the antibody is successfully expressed.

[0061] Example 2: Screening and identification of antibodies Using the indirect ELISA experiment, the two recombinant rabbit monoclonal antibodies screened in Example 1 were subjected to indirect ELISA titer detection. The specific method of detection is: (1) Use carbonate buffer (pH = 9.6, 0.05 M) to mix Dupilumab ( Dupilumab ) for coating, coating concentration 2 μg / mL, 100 μL / well, incubate overnight at 4°C; wash the plate with washing solution; (2) Block with phosphate buffer (pH = 7.2, 0.05 M) containing 3% bovine serum albumin and 0.05% Tween-20, 300 μL / well.

[0062] (3) Pour the blocking solution in the plate into a water pool, wash three times with 1× PBST, 300 μL / well, and pat dry.

[0063] (4) Dilute the two recombinant rabbit monoclonal antibodies in sequence to obtain a total of 7 standard points: 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, 0.0625 g / mL, 0.03125 μg / mL and 0.015625 μg / mL. Finally, use 100 μL of phosphate buffer as the zero standard (i.e., without standard substance) and add it to the ELISA plate, for a total of 8 points. Incubate at 37°C for 1 hour, and then wash the plate with washing solution. (5) Pour the primary antibody in the plate into a water pool, wash three times with 1× PBST, 300 μL / well, and pat dry.

[0064] (6) Add horseradish peroxidase-labeled goat anti-rabbit secondary antibody (Jackson Immunoresearch, Catalog No. 111-035-045) diluted in phosphate buffer; the working concentration of the secondary antibody is 0.08 μg / mL, 100 μL / well, and incubate at 37°C for 30 min.

[0065] (7) Washing the plate: Pour the secondary antibody in the plate into the water pool, wash three times with 1×PBST, 300 μL / well, and pat dry.

[0066] (8) Color development: Add TMB at 100 μL / well and incubate at 37°C for 10 min.

[0067] (9) Termination and reading: Add 2 M HCl at 50 μL / well to terminate the reaction and read the sample immediately. Read the sample at a wavelength of 450-620 nm on an ELISA reader, export the data and save it. The test results are shown in Table 2 below.

[0068] Table 2 Elisa results of recombinant rabbit monoclonal antibody (OD 450 and OD 620 The difference of

[0069] The Biacore 8000 biomolecular interaction analyzer was used to analyze the dupilumab ( Dupilumab The affinity of the selected primary and secondary antibodies was precisely determined using rabbit monoclonal antibodies. The concentration of the selected primary and secondary antibodies was 50 nM, respectively, and they were immobilized on a CM5 chip (GE Healthcare).

[0070] Then, five concentrations of dupilumab (50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.125 nM) were used for the first antibody. Dupilumab ) to bind and obtain the affinity curve, such as Figure 4 shown.

[0071] For the secondary antibody, five concentrations of dupilumab (50 nM, 25 nM, 12.5 nM, 6.25 nM, and 3.125 nM) were used. Dupilumab ) to bind and obtain the affinity curve, such as Figure 5 shown.

[0072] Figure 4 , 5 In the figure, the horizontal axis is the reaction time, the vertical axis is the response value, and the colored lines are the response values ​​under different concentrations of antibody loading. The binding constant Ka and dissociation constant Kd are obtained according to the response value. The affinity value KD is calculated according to the formula KD=Kd / Ka. The smaller the KD value, the stronger the antibody affinity. Generally, the antibody affinity is less than 10 -10 It can be considered that the antibody affinity is very high. Tables 3 and 4 below are the test results of the affinity of the first antibody and the second antibody respectively.

[0073] Table 3 Affinity test results of the first antibody

[0074] Table 4 Affinity test results of the second antibody

[0075] From Table 3-4 and Figure 4-5 It can be seen that the affinity of the first antibody of Dupilumab rabbit monoclonal antibody was finally obtained by curve fitting and calculation, which was 7.36×10 -11 M; the affinity of the secondary antibody of dupilumab rabbit monoclonal antibody is 9.44×10 -11 M.

[0076] The heavy and light chains of the first antibody and the complete sequences of the heavy and light chains of the second antibody were obtained by entrusting a third-party company (Qingke Biotechnology) to sequence. Then, according to the Kabat rule (reference: Kabat EA, Wu TT, Bilofsky H. Attempts to locate residues incomplementarity-determining regions of antibody combining sites that make contact with antigen. Proc. Natl. Acad. Sci. USA. 1976; 73: 617–619), the sequences of the heavy and light chains of the two antibodies (i.e., the first antibody and the second antibody) were obtained.

[0077] The anti-duplimab ( Dupilumab ) The amino acid sequence of the heavy chain of the first antibody of the rabbit monoclonal antibody is: QSVEESGGRLVTPGTPLTLTCKASGFSLSRYWMSWVRQAPGEGLEWIGYISSGGSSYYATWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARDAGYTIGTPLNIWGPGT LVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTC PPPELLGGPSVFIFPPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLREQQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAPIEKTISKAR GQPLEPKVYTMGPPREELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYSKLSVPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPGK, as in SEQ Shown as IDNO.8.

[0078] The amino acid sequence of the light chain of the first antibody is: DVVMTQTPASVSEPVGDTVTIKCQASEDIESYLAWYQQKPGQPPKLLIYGASNLESGVPSRFKGSGSGTEYTLTISDLECADAATYYCQCTYYPDNAFGGGTEVVVKG DPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC, as in SEQ Shown as IDNO.9.

[0079] Wherein, the amino acid sequence of the heavy chain variable region of the first antibody is: QSVEESGGRLVTPGTPLTLTCKASGFSLSRYWMSWVRQAPGEGLEWIGYISSGGSSYYATWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARDAGYTIGTPLNIWGPGTLVTVSS, as shown in SEQ ID NO.6.

[0080] The amino acid sequence of the light chain variable region of the first antibody is: DVVMTQTPASVSEPVGDTVTIKCQASEDIESYLAWYQQKPGQPPKLLIYGASNLESGVPSRFKGSGSGTEYTLTISDLECADAATYYCQCTYYPDNAFGGGTEVVVK, as shown in SEQ ID NO.7.

[0081] The amino acid sequence of the complementary determining region CDR1 on the heavy chain of the first antibody is GFSLSRYW, as shown in SEQ ID NO.1; The amino acid sequence of the complementary determining region CDR2 on the heavy chain of the first antibody is ISSGGSS, as shown in SEQ ID NO.2; The amino acid sequence of the complementary determining region CDR3 on the heavy chain of the first antibody is ARDAGYTIGTPLNI, as shown in SEQ ID NO.3; The amino acid sequence of the complementary determining region CDR1 on the light chain of the first antibody is EDIESY, as shown in SEQ ID NO.4; The amino acid sequence of the complementary determining region CDR2 on the light chain of the first antibody is GAS; The amino acid sequence of the complementary determining region CDR3 on the light chain of the first antibody is QCTYYPDNA, as shown in SEQ ID NO.5.

[0082] The anti-duplimab ( Dupilumab ) The amino acid sequence of the heavy chain of the secondary antibody of the rabbit monoclonal antibody is: QSVEESGGRLVTPGTPLTLTCTVSGIDLSSYAMSWVRQAPGKGLEWIGIISISGSTYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARYDTYDDYGDYDGFNLWGP GTLVTVSSGQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTLTNGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVDKTVAPSTCSKPTC PPPELLGGPSVFIFPPPKPKDTLMISRTPEVTCVVVDVSQDDPEVQFTWYINNEQVRTARPPLREQQFNSTIRVVSTLPIAHQDWLRGKEFKCKVHNKALPAPIEKTISKARG QPLEPKVYTMGPPREELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDSDGSYFLYSKLSVPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSPGK, such as SEQID Shown in NO.17.

[0083] The amino acid sequence of the light chain of the second antibody is: ALVMTQTPASVEAAVGGTVTIKCQASQSIYSNLAWYQQKPGQPPNLLIYAASYLASGVSSRFKGSGSGTQFTLTISDLECADAATYYCQQDYTNNDVDNTFGGGTEVVVK GDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC, such as SEQID Shown in NO.18.

[0084] Wherein, the amino acid sequence of the heavy chain variable region of the second antibody is: QSVEESGGRLVTPGTPLTLTCTVSGIDLSSYAMSWVRQAPGKGLEWIGIISISGSTYYASWAKGRFTISKTSTTVDLKITSPTTEDTATYFCARYDTYDDYGDYDGFNLWGPGTLVTVSS, as shown in SEQ ID NO.15.

[0085] The amino acid sequence of the light chain variable region of the second antibody is: ALVMTQTPASVEAAVGGTVTIKCQASQSIYSNLAWYQQKPGQPPNLLIYAASYLASGVSSRFKGSGSGTQFTLTISDLECADAATYYCQQDYTNNDVDNTFGGGTEVVVK, as shown in SEQ ID NO.16.

[0086] The amino acid sequence of the complementary determining region CDR1 on the heavy chain of the second antibody is GIDLSSYA, as shown in SEQ ID NO.10; The amino acid sequence of the complementary determining region CDR2 on the heavy chain of the second antibody is ISISGST, as shown in SEQ ID NO.11; The amino acid sequence of the complementary determining region CDR3 on the heavy chain of the second antibody is ARYDTYDDYGDYDGFNL, as shown in SEQ ID NO.12; The amino acid sequence of the complementary determining region CDR1 on the light chain of the second antibody is QSIYSN, as shown in SEQ ID NO.13; The amino acid sequence of the complementarity determining region CDR2 on the light chain of the second antibody is AAS; The amino acid sequence of the complementary determining region CDR3 on the light chain of the second antibody is QQDYTNNDVDNT, as shown in SEQ ID NO.14.

[0087] Example 3: Anti-duplimab ( Dupilumab ) Sensitivity test of rabbit monoclonal antibody primary antibody and secondary antibody Using the obtained anti-duplimab ( Dupilumab ) Rabbit monoclonal antibody was used as the primary antibody and the secondary antibody to explore the conditions of competitive enzyme-linked immunosorbent assay.

[0088] 1. Use carbonate buffer (pH=9.6, 0.05 M) to coat the recombinant protein IL4R at a coating concentration of 1 μg / mL, 100 μL / well, incubate overnight at 4°C; wash the plate with washing solution.

[0089] 2. Block with phosphate buffer (pH=7.2, 0.05 M) containing 3% bovine serum albumin and 0.05% Tween-20.

[0090] 3. Anti-duplimab ( Dupilumab) Rabbit monoclonal antibody primary antibody and secondary antibody were diluted in phosphate buffer in turn to obtain a total of 7 standard points of 800 ng / mL, 400 ng / mL, 200 ng / mL, 100 ng / mL, 50 ng / mL, 25 ng / mL, and 12.5 ng / mL. Finally, phosphate buffer was used as the zero standard, a total of 8 standard points, and added to the ELISA plate, 50 μL per well. Dupilumab was diluted to 100 ng / mL with phosphate buffer, added to the ELISA plate at 50 μL per well, mixed, incubated at 37°C for 1 h, and then washed with washing solution.

[0091] 4. Add horseradish peroxidase-labeled goat anti-rabbit secondary antibody (Jackson Immunoresearch, Catalog No. 111-035-045) diluted in phosphate buffer; the working concentration of the secondary antibody is 0.08 μg / mL, incubate at 37°C for 0.5 h, and then wash the plate with washing solution.

[0092] 5. Add TMB colorimetric solution and color at room temperature for 10 min; add 50 μL 2 M hydrochloric acid to stop color development, and then measure the absorbance at wavelengths of 450 nm and 630 nm, respectively. Use OD 450 Subtract OD 630 The inhibition rate was calculated for the corrected absorbance value. The inhibition rate calculation formula is: inhibition rate = (1-sample or standard OD value / blank control OD value) × 100%.

[0093] 6. Draw a standard curve with the logarithmic value of the concentration of anti-Dupilumab rabbit monoclonal antibody as the horizontal axis and the inhibition rate as the vertical axis. Figure 6 As shown, the experimental results showed that in the competitive enzyme-linked immunosorbent assay method established based on the first antibody and the second antibody of the anti-Dupilumab rabbit monoclonal antibody, the first antibody was a competitive antibody with an IC50 of 64.59 ng / mL, and the second antibody was a non-competitive antibody.

[0094] Example 4: Performance test of the first antibody and the second antibody of the anti-Dupilumab rabbit monoclonal antibody 1. Specificity detection

[0095] Human IgG4 and total human IgG, which are consistent with the subtype of Dupilumab, were used to detect the specificity of the primary and secondary antibodies against Dupilumab rabbit monoclonal antibodies.

[0096] The indirect enzyme-linked immunosorbent assay was used, with Dupilumab, human IgG4 and total human IgG coated, the primary antibody and the secondary antibody used as detection antibodies, and the coating concentrations of Dupilumab, human IgG4 and total human IgG were all 1 μg / mL.

[0097] like Figure 7 As shown, based on the indirect enzyme-linked immunosorbent assay method of the first antibody and the second antibody provided by the present invention, the first antibody and the second antibody of the anti-Dupilumab rabbit monoclonal antibody have no cross-reaction to human IgG4 and human total IgG. This indicates that the first antibody and the second antibody provided by the present invention have high specificity for Dupilumab.

[0098] 2. Thermal stability test The first and second antibodies of rabbit monoclonal antibodies against Dupilumab were placed in a 37°C incubator and sampled on the 14th day. Dupilumab was detected by indirect enzyme-linked immunosorbent assay, with untreated first and second antibodies (i.e., the first and second antibodies were kept in a -20°C environment, respectively) as control samples. Reaction curves were established for antibody samples treated at 37°C for 14 days and untreated control samples.

[0099] like Figure 8 , 9 As shown, after the first and second antibodies of the rabbit monoclonal antibodies against Dupilumab provided by the present invention were treated at 37°C for 14 days, there was no obvious precipitation or deterioration of the antibodies, no obvious decrease in concentration, and no obvious decrease in the indirect enzyme-linked immunosorbent assay signal, and the results showed that the signal decrease was less than 5%. This shows that the first and second antibodies of the rabbit monoclonal antibodies against Dupilumab provided by the present invention have strong thermal stability.

[0100] The above specific embodiments describe the implementation of the present invention in detail, but the present invention is not limited to the specific details in the above embodiments. Within the scope of the claims and technical concept of the present invention, the technical solution of the present invention can be modified and changed in many simple ways, and these simple modifications all belong to the protection scope of the present invention.

Claims

1. A high-affinity rabbit monoclonal antibody against dupilumab, characterized in that: The high-affinity rabbit monoclonal antibody is the first antibody or the second antibody; The amino acid sequence of the complementary determining region CDR1 on the heavy chain of the first antibody is shown in SEQ ID NO.1; The amino acid sequence of the complementary determining region CDR2 on the heavy chain of the first antibody is shown in SEQ ID NO.2; The amino acid sequence of the complementary determining region CDR3 on the heavy chain of the first antibody is shown in SEQ ID NO.3; The amino acid sequence of the complementary determining region CDR1 on the light chain of the first antibody is shown in SEQ ID NO.4; The amino acid sequence of the complementary determining region CDR2 on the light chain of the first antibody is GAS; The amino acid sequence of the complementary determining region CDR3 on the light chain of the first antibody is shown in SEQ ID NO.5; The amino acid sequence of the complementary determining region CDR1 on the heavy chain of the second antibody is shown in SEQ ID NO.10; The amino acid sequence of the complementary determining region CDR2 on the heavy chain of the second antibody is shown in SEQ ID NO.11; The amino acid sequence of the complementary determining region CDR3 on the heavy chain of the second antibody is shown in SEQ ID NO.12; The amino acid sequence of the complementary determining region CDR1 on the light chain of the second antibody is shown in SEQ ID NO.13; The amino acid sequence of the complementary determining region CDR2 on the light chain of the second antibody is AAS; The amino acid sequence of the complementary determining region CDR3 on the light chain of the second antibody is shown in SEQ ID NO.

14.

2. The high-affinity rabbit monoclonal antibody against dupilumab according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region of the first antibody is shown in SEQ ID NO.6; the amino acid sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.7; The amino acid sequence of the heavy chain variable region of the second antibody is shown in SEQ ID NO.15; the amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.

16.

3. The high-affinity rabbit monoclonal antibody against dupilumab according to claim 2, characterized in that: The amino acid sequence of the heavy chain of the first antibody is shown in SEQ ID NO.8; the amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.9; The amino acid sequence of the heavy chain of the second antibody is shown in SEQ ID NO.17; the amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.

18.

4. A substance, characterized in that The substance includes any one of the following aspects: (1) A nucleic acid molecule or a vector comprising the nucleic acid molecule, wherein the nucleic acid encodes the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3; (2) A modified cell or recombinant strain, wherein the modified cell or recombinant strain is used to express the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3; (3) An antibody derivative, comprising the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3; (4) A drug, comprising a pharmaceutical composition comprising a therapeutically effective amount of the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3, or the antibody derivative; (5) A detection product, comprising the high-affinity rabbit monoclonal antibody according to any one of claims 1 to 3, or the nucleic acid molecule, or the vector, or a derivative of the high-affinity rabbit monoclonal antibody.

5. The substance according to claim 4, characterized in that The detection product is a competitive ELISA detection kit for detecting dupilumab.

6. The substance according to claim 5, characterized in that In the competitive ELISA detection kit for detecting dupilumab, the first antibody is a competitive antibody and the second antibody is a non-competitive antibody.

7. Use of the high-affinity rabbit monoclonal antibody against dupilumab according to any one of claims 1 to 3, characterized in that: Used to detect dupilumab for purposes other than disease diagnosis and treatment; or, used to prepare products for detecting dupilumab; or, used to prepare products for modulating the activity of dupilumab.

8. The use of the high-affinity rabbit monoclonal antibody of dupilumab according to claim 7, characterized in that: The product is a detection reagent, a detection kit, a detection test strip, a detection probe or a detection chip.

Citation Information

Patent Citations

  • Anti-human ROR1 high-affinity rabbit monoclonal antibody and application thereof

    CN115724973A

  • High-affinity Human IL-5 rabbit monoclonal antibody and application thereof

    CN115819578A

  • Antibody variable domains that bind IL-4R

    CN116888151A

  • Anti-mouse interleukin 10 rabbit monoclonal antibody and application thereof

    CN117362431A

  • Anti-IL-4R antibodies and uses thereof

    CN117924490A